Sernova Corp. (SVA.TO) TSX

0.17

+0.01(+6.45%)

Updated at June 02 03:43PM

Currency In CAD

Sernova Corp.

Address

The Stiller Centre

London, ON N6G 4X8

United Kingdom of Great Britain and Northern Ireland (the)

Phone

519 858 5184

Sector

Healthcare

Industry

Biotechnology

Employees

17

First IPO Date

April 29, 1999

Key Executives

NameTitlePayYear Born
Jonathan N. RigbyPresident, CEO & Director980,6131968
David BurkeVice President of Investor Relations163,151N/A
Pericles CaliasChief Development Officer and Head of R&D336,2961968
James T. ParsonsChief Financial Officer471,9001965
Marylyn RigbyChief Communications Officer521,125N/A

Description

Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.